Principles of Clinical Pharmacology¶
Jr., A. J. A., Huang, S., Lertora, J. J. L., & Markey, S. P. (2012). Principles of Clinical Pharmacology. Academic Press.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- PK/PD Modeling (Pharmacokinetics / Pharmacodynamics)
- PK/PD modeling appears in drug development (dose selection for first-in-human trials using preclinical PK/PD scaling; dose-finding in Phase 1–2; dose justification for regulatory submission); in clinical pharmacology (therapeutic drug monitoring for aminoglycosides, vancomycin, anticonvulsants; dosing in special populations — pediatrics, obesity, renal impairment); in anesthesiology (target-controlled infusion of intravenous anesthetics based on PK/PD model-driven dosing); in oncology (chemotherapy dose individualization based on clearance and target effect); in antimicrobial therapy (time-above-MIC, peak/MIC, AUC/MIC targets derived from PK/PD); in pediatric dosing (scaling from adult to pediatric PK/PD); in veterinary medicine (cross-species scaling); and in toxicology (toxicokinetic-toxicodynamic modeling for risk assessment), as catalogued by Atkinson, Huang, Lertora, and Markey (2012) across the principles of clinical pharmacology.
This sourceStandard clinical pharmacology reference: catalogues PK/PD application across drug development, therapeutic drug monitoring, special-population dosing, and regulatory science.
- PK/PD modeling appears in drug development (dose selection for first-in-human trials using preclinical PK/PD scaling; dose-finding in Phase 1–2; dose justification for regulatory submission); in clinical pharmacology (therapeutic drug monitoring for aminoglycosides, vancomycin, anticonvulsants; dosing in special populations — pediatrics, obesity, renal impairment); in anesthesiology (target-controlled infusion of intravenous anesthetics based on PK/PD model-driven dosing); in oncology (chemotherapy dose individualization based on clearance and target effect); in antimicrobial therapy (time-above-MIC, peak/MIC, AUC/MIC targets derived from PK/PD); in pediatric dosing (scaling from adult to pediatric PK/PD); in veterinary medicine (cross-species scaling); and in toxicology (toxicokinetic-toxicodynamic modeling for risk assessment), as catalogued by Atkinson, Huang, Lertora, and Markey (2012) across the principles of clinical pharmacology.
Verification¶
Does it exist? Not checked yet. This entry carries no identifier to resolve. It was extracted from the citation as written in the article, normalized, and deduplicated against the rest of the registry.
Does it back the claim? Not recorded. The single citation of this work carries no recorded support check.
Was it audited? Yes. A second, independent pass read the citation against the article text and recorded a verdict.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:13521e8a78ad · see in the full table